November 14th 2024
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Molecular Testing Benefits Patients as Targeted Therapies Continue to Evolve for Metastatic NSCLC
September 7th 2019In a recent analysis published in <em>JAMA</em>, data were evaluated from a collection of clinical trials and analyzed for important takeaways in the testing and treatment of patients with non–small cell lung cancer. The authors stress the importance of molecular testing in patients with NSCLC as more targeted therapies become available. <br />
Read More
Langer Describes the Best Courses of Treatment for Stage III and IV NSCLC in 2 Case Studies
September 5th 2019Corey J. Langer, MD, detailed the best courses of treatment for a patient with non–small cell lung cancer to a group of physicians during a recent Targeted Oncology live case-based peer perspectives discussion.
Read More
Considering the Role of Clinical Trials for Patients With Molecularly Altered Lung Cancers
September 3rd 2019Sarah B. Goldberg, MD, MPH, discusses the role of clinical trials in patients with lung cancer who have molecularly altered tumors, such as <em>EGFR</em>, <em>ALK</em>, <em>BRAF</em>,<em>ROS1, </em>or other alterations. These patients typically consider either targeted therapy or immunotherapy treatment options.
Watch
FDA Extends Review Period for Frontline Atezolizumab Combo in Nonsquamous NSCLC
September 3rd 2019The review period has been extended by the FDA for a supplemental biologics license application for atezolizumab as a frontline treatment for patients with metastatic nonsquamous non–small cell lung cancer who do not have <em>EGFR</em> or <em>ALK</em> aberrations, in combination with carboplatin and nab-paclitaxel.
Read More
Phase II Data Suggest Predictive Value of Preexisting CD8+ T Cells in SCLC
August 28th 2019Findings from a phase II study in patients with small cell lung cancer suggested tumor immune phenotypes can be predictive of response to immune checkpoint blockade. Responses to the combination of durvalumab plus olaparib were observed in all patients where tumors had an inflamed phenotype.
Read More
Discussing the Benefits of Trilaciclib Plus Topotecan for Treatment of Extensive-stage SCLC
August 27th 2019Lowell L. Hart, MD, FACP, scientific director of clinical research, Florida Cancer Specialists & Research Institute, and associate professor of medicine, Wake Forest University School of Medicine, discusses the effect of CDK4/6 inhibitor, trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. Hart presented the phase II results from the blinded, multicenter study during the 2019 ASCO Annual Meeting.
Watch
PFS Doubling Observed in Patients With EGFR+ NSCLC With Addition of Platinum to Gefitinib
August 26th 2019The addition of carboplatin and pemetrexed to therapy with gefitinib in patients with non–small cell lung cancer and an <em>EGFR</em>-sensitizing mutation had a statistically significant effect on progression-free survival and overall survival and represents a new therapy option for these patients.
Read More
Precision Medicine Trials and Molecular Testing Guidelines Expand to Reach More Patients
August 21st 2019During the <em>20th Annual </em>International Lung Cancer Congress, <em>Targeted Oncology</em> spoke with another Lung-MAP investigator, Fred R. Hirsch, MD, PhD, about the status and importance of the trial and new recommendations for molecular testing and liquid biopsies working their way into practice in the lung cancer field.
Read More
OS Results Fall Flat With Durvalumab/Tremelimumab Combo in NEPTUNE Trial
August 21st 2019The combination of durvalumab and tremelimumab did not meet its primary overall survival endpoint compared with platinum-based chemotherapy in patients with previously untreated stage IV non–small cell lung cancer and a high tumor mutational burden, according to final OS results from the phase III NEPTUNE trial.
Read More
New Quality Initiative for Patients With Advanced Lung Cancer Improves Care, Coordination
August 16th 2019Twenty to 30 years ago, delivering a diagnosis of lung cancer to a patient was a difficult conversation to have for many oncologists. But that has given way to greater optimism today, according to Mark A. Socinski, MD.
Read More
FDA Approves Entrectinib for ROS1+ NSCLC and NTRK+ Solid Tumors
August 16th 2019The FDA has approved entrectinib for the treatment of adult patients with <em>ROS1</em>-positive metastatic non–small cell lung cancer. An accelerated approval was also granted to entrectinib for the treatment of adult and adolescent patients with solid tumors harboring an <em>NTRK </em>gene fusion and who have no alternative, effective therapies available.
Read More
Research Investigates Role of Antiangiogenic Agents and Checkpoint Inhibitors in EGFR NSCLC
August 13th 2019Heather A. Wakelee, MD, discusses recent research investigating antiangiogenic agents and checkpoint inhibitors in the frontline for patients with <em>EGFR</em>-positive non—small cell lung cancer. The most promising data were demonstrated in the phase III IMpower150 trial.
Watch
Immunotherapies Show Promising Advancements in Small Cell Lung Cancer
August 13th 2019Although chemotherapy remains the standard treatment for small cell lung cancer in first- and second-line settings, notable progress in immunotherapies have recently taken place, begging the question of how these agents will be optimized in this tumor type.
Read More
Osimertinib Benefit Maintained in New OS Findings from FLAURA Trial in EGFR+ NSCLC
August 9th 2019Osimertinib has demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with standard first-generation EGFR tyrosine kinase inhibitors in patients with newly diagnosed <em>EGFR</em>-mutated non–small cell lung cancer, according to updated findings from the phase III FLAURA trial.
Read More
Langer Reviews a Case Study of a Patient With Stage III NSCLC
August 9th 2019During a recent <em>Targeted Oncology </em>live case-based peer perspectives presentation, Corey J. Langer, MD, discussed with a group of physicians the diagnostic workup and the considerations for treatment he makes when seeing a patient with non–small cell lung cancer in the clinic. Langer, director of thoracic oncology, Abramson Cancer Center, and professor of medicine, Hematology/Oncology Division, University of Pennsylvania, reviewed treatment options based on a case study of a patient with stage III NSCLC.
Read More
Novel Therapies Show Early Potential for Treatment of KRAS+ NSCLC
August 5th 2019Studies combining KRAS inhibitor AMG 510 several other is the start of a hopeful era for the treatment of KRAS-mutant non–small cell lung cancer, according to Vassiliki Papadimitrakopoulou, MD, at the 2019 International Lung Cancer Congress.
Read More
Understanding the Difference Between Precision Medicine and Personalized Care for Lung Cancer
August 5th 2019Ravi Salgia, MD, professor and chair, Department of Medical Oncology & Therapeutics Research, associate director for clinical sciences, City of Hope, Durante, California, says there is a difference between precision medicine and personalized medicine.
Watch
Real-World Data Show Long-Term Survival With Sequential Afatinib and Osimertinib in EGFR+ NSCLC
August 2nd 2019Sequential afatinib followed by osimertinib has demonstrated a long-term overall survival of close to 4 years in patients with non–small cell lung cancer who have <em>EGFR </em>deletion 19–positive tumors and acquired T790M mutations, according to interim results released from the real-world GioTag study.
Read More
Survival Benefit With Nivolumab Still Seen at 5 Years in Melanoma, RCC, and NSCLC
July 31st 2019Nivolumab demonstrated long-term survival benefit in heavily pretreated patients with advanced melanoma, renal cell carcinoma, and non–small cell lung cancer, according to an analysis of 5-year results from the CA209-003 trial. The analysis also identified favorable and adverse factors associated with survival that could inform future use of nivolumab.
Read More